Source-grounded facts extracted from Q/C TECHNOLOGIES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Q/C TECHNOLOGIES, INC. engaged Grassi & Co., CPAs, P.C. as its auditor.
“On March 9, 2026, the Committee engaged Grassi & Co., CPAs, P.C. (“Grassi”) as the Company’s independent registered public accounting firm to audit the Company’s financial statements for the year ended December 31, 2025, effective immediately.”
Q/C TECHNOLOGIES, INC. dismissed Stephano Slack LLC as its auditor.
“On March 9, 2026, the Audit Committee of the Board of Directors (the “Committee”) of Q/C Technologies, Inc. (the “Company”) approved the dismissal of Stephano Slack LLC (“Stephano Slack”) as the Company’s independent registered public accounting firm, effective as of the same date.”
Q/C TECHNOLOGIES, INC. issued 212,500 restricted shares of Common Stock of common stock to Ocean Avenue Holdings LLC.
“(iii) grant to the Consultant 212,500 restricted shares of Common Stock, which vest in four substantially equal installments on the quarterly anniversaries of the issuance date”
Q/C TECHNOLOGIES, INC. issued up to an aggregate of 212,500 shares of common stock of warrant to Ocean Avenue Holdings LLC.
“(ii) issue warrants to purchase up to an aggregate of 212,500 shares of common stock, par value $0.001 per share (“Common Stock”), of the Company at an exercise price equal to $5.097 per share”
Q/C TECHNOLOGIES, INC. issued a warrant to purchase up to 100,000 shares of Common Stock at an exercise price of $5.00 per share (the 'First Tranche Warrant') of warrant to James Altucher and Z-List Media, Inc. for consulting services.
“Pursuant to the Altucher Consulting Agreement, the Company agreed to issue to Z-List Media, Inc. warrants to purchase up to an aggregate of 400,000 shares of Common Stock, consisting of: (i) a warrant to purchase up to 100,000 shares of Common Stock at an exercise price of $5.00 per share (the “First Tranche Warrant”), which were issued on the date of the Altucher Consulting Agreement (such date, the “Effective Date”),”
Q/C TECHNOLOGIES, INC. issued certain warrants (the 'Warrants') to purchase shares of the Company's common stock, par value $0.001 per share, subject to adjustment of warrant to certain accredited investors (the 'Holders').
“On September 2, 2025, Q/C Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “SPA”) with certain accredited investors (the “Holders”) pursuant to which it agreed to sell to the Holders in a private placement (i) shares of the Company’s Series H convertible preferred stock, par value $0.001 per share, with a stated value of $1,000 per share (the “Preferred Stock”), and (ii) certain warrants (the “Warrants”) to purchase shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), subject to adjustment (collectively, the “Private Placement”).”
Q/C TECHNOLOGIES, INC. issued shares of the Company's Series H convertible preferred stock, par value $0.001 per share, with a stated value of $1,000 per share of preferred stock to certain accredited investors (the 'Holders') for stated value of $1,000 per share.
“On September 2, 2025, Q/C Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “SPA”) with certain accredited investors (the “Holders”) pursuant to which it agreed to sell to the Holders in a private placement (i) shares of the Company’s Series H convertible preferred stock, par value $0.001 per share, with a stated value of $1,000 per share (the “Preferred Stock”), and (ii) certain warrants (the “Warrants”) to purchase shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), subject to adjustment (collectively, the “Private Placement”).”
Q/C TECHNOLOGIES, INC.: Changed corporate name from TNF Pharmaceuticals, Inc. to Q/C Technologies, Inc (effective 2025-09-22).
“On September 22, 2025, the Company filed a Certificate of Amendment to Q/C Technologies, Inc. (the “Company”) Certificate of Incorporation (the “Certificate of Amendment”) to change the name of the Company from “TNF Pharmaceuticals, Inc.” to “Q/C Technologies, Inc.” effective as of September 22, 2025 (the “Name Change”).”
Q/C TECHNOLOGIES, INC.: Filed Certificate of Amendment to Certificate of Incorporation to effect a 1-for-100 reverse stock split of Common Stock (effective 2025-08-29).
“On August 29, 2025, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to the Certificate of Incorporation of the Company (the “Certificate of Incorporation”) with the Secretary of State of Delaware to effect a 1-for-100 reverse stock split of the shares of the Company’s Common Stock either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (New York time) on August 29, 2025 (the “Reverse Stock Split”).”
Q/C TECHNOLOGIES, INC.: Increased authorized common stock from 250,000,000 to 1,250,000,000 shares and corresponding change to total authorized capital stock (effective 2025-06-06).
“On June 3, 2025, TNF Pharmaceuticals, Inc. (the “Company”) reconvened its 2025 annual meeting of stockholders, which was adjourned from May 20, 2025 (the “Annual Meeting”). At the Company’s Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation (the “Share Increase Amendment”) to increase the number of authorized shares of common stock, par value $0.001 per share (“Common Stock”), from 250,000,000 shares to 1,250,000,000 and to make a corresponding change to the number of authorized shares of the Company’s capital stock. Following the Annual Meeting, on June 6, 2025, the Company filed the Share Increase Amendment with the Secretary of State of the State of Delaware.”
Stephen Friscia was appointed as Director at Q/C TECHNOLOGIES, INC..
“On June 13, 2024, Mr. Stephen Friscia was appointed to serve as a member of the Board until his successor has been duly elected and qualified or until his earlier resignation or removal.”
Mitchell Glass was appointed as President and Chief Medical Officer at Q/C TECHNOLOGIES, INC..
“On June 13, 2024, the Company appointed Mitchell Glass, M.D., a current member of the Board, to the positions of President and Chief Medical Officer, effective as of June 13, 2024.”
Christopher Chapman resigned as President and Chief Medical Officer at Q/C TECHNOLOGIES, INC..
“the Company and Christopher Chapman, M.D. mutually agreed on the separation of Dr. Chapman from his position as President, Chief Medical Officer and member of the board of directors”
Adam Kaplin resigned as Chief Scientific Officer at Q/C TECHNOLOGIES, INC..
“On April 15, 2024, Adam Kaplin, M.D., Ph.D., who served as Chief Scientific Officer of MyMD Pharmaceuticals, Inc. (the “Company”), tendered his resignation from his role as an officer of the Company, effective immediately.”
Q/C TECHNOLOGIES, INC. amended Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock with Required Holders valued at Amends voting rights and director election rights for holders of Series F Convertible Preferred Stoc (effective 2024-04-08).
“The Amended and Restated Certificate of Designations was filed with the Secretary of State of the State of Delaware, effective as of April 8, 2024.”
Q/C TECHNOLOGIES, INC. amended Omnibus Waiver and Amendment with Required Holders valued at Deferred installment amounts due March 1, 2024 and April 1, 2024 to May 1, 2024; waived breaches; am (effective 2024-04-05).
“On April 5, 2024, the Company entered into an Omnibus Waiver and Amendment (the “Omnibus Agreement”) with the Required Holders (as defined in the Certificate of Designations).”
Mitchell Glass was appointed as Director at Q/C TECHNOLOGIES, INC..
“the Company increased the authorized number of directors from six (6) to seven (7) and appointed Mitchell Glass to serve as a member of the Company’s board of directors”
Q/C TECHNOLOGIES, INC. entered into Plan of Merger with MyMD New Jersey, MyMD Delaware (effective 2024-03-04).
“MyMD Pharmaceuticals, Inc., a New Jersey corporation (“MyMD New Jersey” or, prior to the Reincorporation (as defined below), the “Company”) merged with and into its wholly-owned subsidiary, MyMD Pharmaceuticals, Inc., a Delaware corporation (“MyMD Delaware” or, following the Reincorporation, the “Company”), with MyMD Delaware being the surviving corporation, pursuant to that certain Agreement and Plan of Merger, dated as of March 4, 2024, by and between MyMD New Jersey and MyMD Delaware (the “Plan of Merger”)”
Q/C TECHNOLOGIES, INC.: Certificate of Amendment filed to effect a 1-for-30 reverse stock split and reduce authorized shares from 500 million to 16,666,666 (effective 2024-02-14).
“On February 13, 2024, MyMD Pharmaceuticals, Inc. (the " Company ") announced that it had filed with the Secretary of State of the State of New Jersey a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the " Charter Amendment ") to effect a 1-for-30 reverse stock split (the " Reverse Stock Split ") of the Company’s common stock, without par value (the " Common Stock "), effective as of 4:05 p.m. Eastern Standard Time on February 14, 2024 (the " Effective Time ").”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.